Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is being done to answer the following question: Can testing breast cancer for DNA abnormalities or "biomarkers" help predict which patients are most likely to be helped by certain treatments? The pre-study screening is being done to test a sample of blood (or tumour tissue) for biomarkers to see if patients can participate in the study
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie zaawansowany/przerzutowy rak piersi z dodatnim receptorem hormonalnym, bez nadekspresji HER2
- •Dostępna próbka tkanki guza
- •Udokumentowana progresja choroby po pierwszej linii leczenia inhibitorem CDK4/6 z terapią hormonalną (min. 24 tygodnie leczenia)
- •Mierzalna choroba w badaniach obrazowych
- •Wiek od 18 lat
- •Dobry stan sprawności (ECOG 0-1)
- •Oczekiwane przeżycie ≥3 miesiące
- •Prawidłowe wyniki badań krwi, wątroby i nerek
Simplified criteria — AI translation
Trial details
- Last updated (source)
- May 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (10)
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Canada
BCCA - Kelowna
Kelowna, Canada
BCCA - Vancouver
Vancouver, Canada
QEII Health Sciences Centre
Halifax, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Canada
Kingston Health Sciences Centre
Kingston, Canada
Ottawa Hospital Research Institute
Ottawa, Canada
Odette Cancer Centre
Toronto, Canada
University Health Network
Toronto, Canada
The Jewish General Hospital
Montreal, Canada
Trial contact
Lesley Seymour
Laura Pearce
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.